Shulamit Ron Bigger, Ph.D.
About Shulamit Ron Bigger, Ph.D.
Shulamit Ron Bigger, Ph.D., is the Vice President of Portfolio Strategy, Research and Early Development at Bristol Myers Squibb in Princeton, New Jersey. She has over 8 years of experience at the company, holding various leadership roles in oncology and immuno-oncology.
Company
Shulamit Ron Bigger, Ph.D., currently works at Bristol Myers Squibb as Vice President of Portfolio Strategy, Research, and Early Development at their Princeton, New Jersey office. She has been with Bristol Myers Squibb for over 8 years.
Title
Shulamit Ron Bigger holds the title of Vice President of Portfolio Strategy, Research, and Early Development at Bristol Myers Squibb. She has held this position since transitioning from her previous role as Executive Director within the same department.
Professional Background
Prior to her current role, Shulamit served in multiple capacities at Bristol Myers Squibb, including Executive Director (2019-2021), Director of Oncology Early Assets (2017-2019), and Associate Director of Immuno-Oncology Marketing (2015-2017). She also worked as Medical Director at Harrison and Star (2013-2015) and as Associate Medical Director at Flashpoint Medica (2011-2013).
Education and Expertise
Shulamit completed a B.A in Molecular Biochemistry at Technion - Israel Institute of Technology and earned her Ph.D. in Cancer Epigenetics from The Hebrew University of Jerusalem. Her educational background complements her extensive experience in oncology and immuno-oncology.
Career in Oncology and Immuno-Oncology
Shulamit has extensive experience in both marketing and early-stage asset development within the pharmaceutical industry. Her roles at Bristol Myers Squibb have been focused on oncology and immuno-oncology, leveraging her strong background in cancer epigenetics.